Benzo lipoxin analogues

ABSTRACT

Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application and claims the benefit ofpriority under 35 U.S.C. § 120 of U.S. application Ser. No. 14/450,017,filed Aug. 1, 2014, which is a continuation of U.S. application Ser. No.13/372,029, filed Feb. 13, 2012, now U.S. Pat. No. 8,802,881, which is acontinuation of U.S. application Ser. No. 12/711,051, filed Feb. 23,2010, now U.S. Pat. No. 8,115,023, which is a continuation of U.S.patent Ser. No. 11/398,481, filed Apr. 4, 2006, now U.S. Pat. No.7,683,193, which is a continuation of and claims the benefit of priorityunder 35 U.S.C. § 120 of U.S. application Ser. No. 10/938,729, filedSep. 10, 2004, now abandoned, which claims the benefit of priority under35 U.S.C. § 119(e) to U.S. provisional application Ser. No. 60/502,094,filed Sep. 10, 2003. The disclosure of each of the prior applications isconsidered part of and is incorporated by reference in the disclosure ofthis application.

FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

The invention was made with government support under Grant No.PO1-DE13499 awarded by the National Institutes of Health. The governmenthas certain rights in the invention.

FIELD OF THE INVENTION

Compounds, compositions and methods using benzo lipoxin analogs for theprevention, amelioration and treatment of a variety of disorders, suchas inflammatory diseases, autoimmune diseases and proliferativediseases.

BACKGROUND OF THE INVENTION

The lipoxins (LX) are tetraene-containing eicosanoids generated fromarachidonic acid via several pathways involving the combined action ofvarious lipoxygenases. (Science 1987, 237, 1171. Angew. Chem. Int. Ed.Engl. 1991, 30, 1100. Curr. Opin. Hematology 1994, 1, 69. Serhan, C. N.Biochim. Biophys. Acta 1994, 1212, 1. Prostaglandins & other LipidMediators 2002, 68-69, 433.). Two major structural types of LX have beenidentified, namely LXA4 and LXB4 (Scheme 1). The LX are generatedlargely transcellulary (e.g. via interactions between epithelial cellsand neutrophils). Recent studies by Serhan have shown that, whileacetylation of COX-1 by aspirin inhibits prostanoid formation, similaracetylation of COX-2 allows the formation of 15R-HETE, which isconverted to 15-epi lipoxins (aspirin-triggered lipoxins) (Scheme 1).(Curr. Opin. Hematology 1994, 1, 69. Serhan, C. N. Biochim. Biophys.Acta 1994, 1212, 1. Prostaglandins & other Lipid Mediators 2002, 68-69,433.).

A key feature of LX that distinguishes them from most other eicosanoidmediators (or modulators) of inflammation is their potentantiinflammatory actions (Prostaglandins 53:107, 1997; Prostaglandins &other Lipid Mediators 68-69:433, 2002). The in vitro and in vivoactivities of the best-characterized lipoxin, LXA4, include: (a)inhibition of neutrophil chemotaxis, adherence, and transmigration; (b)suppression of neutrophil activation (including NF-kB activation,superoxide generation and elastase secretion); (c) suppression of IL-8production by epithelia and leukocytes; (d) upregulation of bactericidalpermeability-increasing protein expression in epithelial cells; (e)upregulation of monocyte chemotaxis; (f) upregulation of monocyteingestion of apoptotic neutrophils (Prostaglandins 53:107, 1997;Prostaglandins & other Lipid Mediators 68-69:433, 2002; Proc Natl AcadSci USA 99:13266, 2002; Proc Natl Acad Sci USA 99:3902, 2002). In avariety of in vivo models, LX have been shown to preventneutrophil-mediated damage, and promote the resolution ofneutrophil-mediated inflammation (Ernst Schering Res Found Workshop31:143, 2000; Prostaglandins 53:107, 1997; Prostaglandins & other LipidMediators 68-69:433, 2002). Notably, LX analogues have recently beenshown to downmodulate allergic pulmonary inflammatory responses in mousemodels (Biochemistry 1995, 34, 14609. J. Biol. Chem. 1997, 272, 6972.Proc. Nat. Acad. Sci. 1997, 94, 9967. Nature Immunol 8:1018, 2002. JImmunol 2003 170: 2688).

Several studies have established the facile metabolic deactivation ofthe lipoxins. As a result, in order to develop biostable analogs of LX,it is important to modify their structures in order to enhance theirchemical and in vivo stability. Several biostable LX analogs have beenreported. (Biochemistry 1995, 34, 14609).

SUMMARY OF THE INVENTION

The present invention provides new lipoxin analogs and methods for theirpreparation. The invention also provides methods of use of thesecompounds for the treatment of various forms of inflammation, autoimmunedisorders, and diseases associated with undesired cell proliferation,such as cancer.

The present invention describes LX derivatives having aromatic ringsfused on the tetraene moiety in a variety of configurations. These newcompounds are structural analogs of natural LX compounds, such aslipoxin A₄, lipoxin B₄, 15-epi-lipoxin A₄, 15-epi-lipoxin B₄, and otherrelated lipid mediators derived from polyunsaturated fatty acids otherthan arachidonic acid. The described compounds are readily prepared andhave similar biological properties with the natural LX, while they haveenhanced chemical and biological stability.

Provided herein are benzo-lipoxin analogues having the general structure1

wherein:

-   -   A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino        or —OM, where M is a cation selected from the group consisting        of ammonium, tetra-alkyl ammonium, and the cations of sodium,        potassium, magnesium and zinc;    -   W is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo,        hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino,        dialkylamino, acylamino, carboxamido, or sulfonamide;    -   R^(a)-R^(c) are independently selected from a group costing of        hydrogen, alkyl, aryl, acyl or alkoxyacyl;    -   the integer n is zero, one or two;    -   the integer m is one or two;

and wherein the two substituents on the benzene ring are either ortho-,meta- or para-.

Some preferred embodiments of the present invention are benzo-lipoxinanalogues having one of the general structures 2-7,

wherein:

-   -   A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino        or —OM, where M is a cation selected from the group consisting        of ammonium, tetra-alkyl ammonium, and the cations of sodium,        potassium, magnesium and zinc;    -   W is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo,        hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino,        dialkylamino, acylamino, carboxamido, or sulfonamide;    -   R^(a)-R^(c) are independently selected from a group costing of        hydrogen, alkyl, aryl, acyl or alkoxyacyl;    -   the integer n is zero, one or two;    -   the integer m is one or two.

Additional preferred embodiments of the present invention are analogs oflipoxin A4 and have the stereochemistry designated in formulas 8-13.

wherein:

-   -   A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino        or —OM, where M is a cation selected from the group consisting        of ammonium, tetra-alkyl ammonium, and the cations of sodium,        potassium, magnesium and zinc;    -   W is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo,        hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino,        dialkylamino, acylamino, carboxamido, or sulfonamide;    -   R^(a)-R^(c) are independently selected from a group costing of        hydrogen, alkyl, aryl, acyl or alkoxyacyl;    -   the integer n is zero, one or two;    -   the integer m is one or two.

Additional preferred embodiments of the present invention are analogs of15-epi-lipoxin A4 and have the stereochemistry designated in formulas14-19.

wherein:

-   -   A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino        or —OM, where M is a cation selected from the group consisting        of ammonium, tetra-alkyl ammonium, and the cations of sodium,        potassium, magnesium and zinc;    -   W is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo,        hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino,        dialkylamino, acylamino, carboxamido, or sulfonamide;    -   R^(a)-R^(c) are independently selected from a group costing of        hydrogen, alkyl, aryl, acyl or alkoxyacyl;    -   the integer n is zero, one or two;    -   the integer m is one or two.

Another aspect of the present invention is method for the synthesis ofbenzo lipoxin analogs. A common theme in the synthetic approach to thesecompounds is the use of iterative metal-mediated couplings of suitableintermediates (Scheme 1).

wherein:

-   -   G, Q, X and Y are independently selected from a group consisting        of bromo, chloro, iodo, triflyl, diazonium, iodonium, boronic        acid, boronate, borinate, borate, trifluoroborate, stannyl,        perfluorostannyl, silyl, zinc, magnesium or copper.    -   Compound 20 is first reacted with either 21 or 22 followed by        reaction with the other, in the presence of a Pd, Ni or Cu        catalyst, provided that in each case appropriate combinations of        G, Q, X and Y are present in the reacting compounds.    -   Appropriate reaction combinations among 20+21 or 20+22 involve        the combination of compound 20 having G or C selected from a        group consisting of: bromo, chloro, iodo, triflyl, diazonium,        iodonium and a compound 21 or 22 having X and Y independently        selected from a group consisting of boronate, borinate, borate,        trifluoroborate, stannyl, perfluorostannyl, silyl, zinc,        magnesium or copper.    -   The coupling reactions among 20, 21 and 22 can also be carried        out in sequence or in one pot. In particular embodiments,        compounds 20, 21 and 22 can also be connected to a polymeric        chain or other solid phase material.    -   The present invention also describes methods of use of the benzo        lipoxin analogs for the treatment of various forms of        inflammation, autoimmune disorders, and diseases associated with        undesired cell proliferation, such as cancer.

DETAILED DESCRIPTION OF THE INVENTION A. Definitions

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as is commonly understood by one of ordinary skillin the art. All patents, applications, published applications and otherpublications are incorporated by reference in their entirety. In theevent that there are a plurality of definitions for a term herein, thosein this section prevail unless stated otherwise.

As used herein, the nomenclature alkyl, alkoxy, carbonyl, etc. is usedas is generally understood by those of skill in this art.

As used in this specification, alkyl groups can includestraight-chained, branched and cyclic alkyl radicals containing up toabout 20 carbons, or 1 to 16 carbons, and are straight or branched.Exemplary alkyl groups herein include, but are not limited to, methyl,ethyl, propyl, isopropyl, isobutyl, n-butyl, sec-butyl, tert-butyl,isopentyl, neopentyl, tert-pentyl and isohexyl. As used herein, loweralkyl refer to carbon chains having from about 1 or about 2 carbons upto about 6 carbons. Suitable alkyl groups may be saturated orunsaturated. Further, an alkyl may also be substituted one or more timeson one or more carbons with substituents selected from a groupconsisting of C1-C15 alkyl, allyl, allenyl, alkenyl, C3-C7 heterocycle,aryl, halo, hydroxy, amino, cyano, oxo, thio, alkoxy, formyl, carboxy,carboxamido, phosphoryl, phosphonate, phosphonamido, sulfonyl,alkylsulfonate, arylsulfonate, and sulfonamide. Additionally, an alkylgroup may contain up to 10 heteroatoms, in certain embodiments, 1, 2, 3,4, 5, 6, 7, 8 or 9 heteroatom substituents. Suitable heteroatoms includenitrogen, oxygen, sulfur and phosphorous.

As used herein, “cycloalkyl” refers to a mono- or multicyclic ringsystem, in certain embodiments of 3 to 10 carbon atoms, in otherembodiments of 3 to 6 carbon atoms. The ring systems of the cycloalkylgroup may be composed of one ring or two or more rings which may bejoined together in a fused, bridged or spiro-connected fashion.

As used herein, “aryl” refers to aromatic monocyclic or multicyclicgroups containing from 3 to 16 carbon atoms. As used in thisspecification, aryl groups are aryl radicals which may contain up to 10heteroatoms, in certain embodiments, 1, 2, 3 or 4 heteroatoms. An arylgroup may also be optionally substituted one or more times, in certainembodiments, 1 to 3 or 4 times with an aryl group or a lower alkyl groupand it may be also fused to other aryl or cycloalkyl rings. Suitablearyl groups include, for example, phenyl, naphthyl, tolyl, imidazolyl,pyridyl, pyrroyl, thienyl, pyrimidyl, thiazolyl and furyl groups.

As used in this specification, a ring is defined as having up to 20atoms that may include one or more nitrogen, oxygen, sulfur orphosphorous atoms, provided that the ring can have one or moresubstituents selected from the group consisting of hydrogen, alkyl,allyl, alkenyl, alkynyl, aryl, heteroaryl, chloro, iodo, bromo, fluoro,hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino, dialkylamino,acylamino, carboxamido, cyano, oxo, thio, alkylthio, arylthio, acylthio,alkylsulfonate, arylsulfonate, phosphoryl, phosphonate, phosphonamido,and sulfonyl, and further provided that the ring may also contain one ormore fused rings, including carbocyclic, heterocyclic, aryl orheteroaryl rings.

As used herein, alkenyl and alkynyl carbon chains, if not specified,contain from 2 to 20 carbons, or 2 to 16 carbons, and are straight orbranched. Alkenyl carbon chains of from 2 to 20 carbons, in certainembodiments, contain 1 to 8 double bonds, and the alkenyl carbon chainsof 2 to 16 carbons, in certain embodiments, contain 1 to 5 double bonds.Alkynyl carbon chains of from 2 to 20 carbons, in certain embodiments,contain 1 to 8 triple bonds, and the alkynyl carbon chains of 2 to 16carbons, in certain embodiments, contain 1 to 5 triple bonds.

As used herein, “heteroaryl” refers to a monocyclic or multicyclicaromatic ring system, in certain embodiments, of about 5 to about 15members where one or more, in one embodiment 1 to 3, of the atoms in thering system is a heteroatom, that is, an element other than carbon,including but not limited to, nitrogen, oxygen or sulfur. The heteroarylgroup may be optionally fused to a benzene ring. Heteroaryl groupsinclude, but are not limited to, furyl, imidazolyl, pyrrolidinyl,pyrimidinyl, tetrazolyl, thienyl, pyridyl, pyrrolyl, N-methylpyrrolyl,quinolinyl and isoquinolinyl.

As used herein, “heterocyclyl” refers to a monocyclic or multicyclicnon-aromatic ring system, in one embodiment of 3 to 10 members, inanother embodiment of 4 to 7 members, in a further embodiment of 5 to 6members, where one or more, in certain embodiments, 1 to 3, of the atomsin the ring system is a heteroatom, that is, an element other thancarbon, including but not limited to, nitrogen, oxygen or sulfur. Inembodiments where the heteroatom(s) is(are) nitrogen, the nitrogen isoptionally substituted with alkyl, alkenyl, alkynyl, aryl, heteroaryl,aralkyl, heteroaralkyl, cycloalkyl, heterocyclyl, cycloalkylalkyl,heterocyclylalkyl, acyl, guanidino, or the nitrogen may be quaternizedto form an ammonium group where the substituents are selected as above.

As used herein, “aralkyl” refers to an alkyl group in which one of thehydrogen atoms of the alkyl is replaced by an aryl group.

As used herein, “halo”, “halogen” or “halide” refers to F, Cl, Br or I.

As used herein, “haloalkyl” refers to an alkyl group in which one ormore of the hydrogen atoms are replaced by halogen. Such groups include,but are not limited to, chloromethyl and trifluoromethyl.

As used herein, “alkoxy” refers to RO—, in which R is alkyl, includinglower alkyl.

As used herein, “aryloxy” refers to RO—, in which R is aryl, includinglower aryl, such as phenyl.

As used herein “subject” is an animal, typically a mammal, includinghuman, such as a patient.

As used herein, pharmaceutically acceptable derivatives of a compoundinclude salts, esters, enol ethers, enol esters, acetals, ketals,orthoesters, hemiacetals, hemiketals, acids, bases, solvates, hydratesor prodrugs thereof. Such derivatives may be readily prepared by thoseof skill in this art using known methods for such derivatization. Thecompounds produced may be administered to animals or humans withoutsubstantial toxic effects and either are pharmaceutically active or areprodrugs. Pharmaceutically acceptable salts include, but are not limitedto, amine salts, such as but not limited toN,N′-dibenzylethylenediamine, chloroprocaine, choline, ammonia,diethanolamine and other hydroxyalkylamines, ethylenediamine,N-methylglucamine, procaine, N-benzylphenethylamine,1-para-chlorobenzyl-2-pyrrolidin-1′-ylmethylbenzimidazole, diethylamineand other alkylamines, piperazine and tris(hydroxymethyl)aminomethane;alkali metal salts, such as but not limited to lithium, potassium andsodium; alkali earth metal salts, such as but not limited to barium,calcium and magnesium; transition metal salts, such as but not limitedto zinc; and other metal salts, such as but not limited to sodiumhydrogen phosphate and disodium phosphate; and also including, but notlimited to, salts of mineral acids, such as but not limited tohydrochlorides and sulfates; and salts of organic acids, such as but notlimited to acetates, lactates, malates, tartrates, citrates, ascorbates,succinates, butyrates, valerates and fumarates. Pharmaceuticallyacceptable esters include, but are not limited to, alkyl, alkenyl,alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl andheterocyclyl esters of acidic groups, including, but not limited to,carboxylic acids, phosphoric acids, phosphinic acids, sulfonic acids,sulfinic acids and boronic acids. Pharmaceutically acceptable enolethers include, but are not limited to, derivatives of formula C═C(OR)where R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl,heteroaralkyl, cycloalkyl or heterocyclyl. Pharmaceutically acceptableenol esters include, but are not limited to, derivatives of formulaC═C(OC(O)R) where R is hydrogen, alkyl, alkenyl, alkynyl, aryl,heteroaryl, aralkyl, heteroaralkyl, cycloalkyl ar heterocyclyl.Pharmaceutically acceptable solvates and hydrates are complexes of acompound with one or more solvent or water molecules, or 1 to about 100,or 1 to about 10, or one to about 2, 3 or 4, solvent or water molecules.

As used herein, treatment means any manner in which one or more of thesymptoms of a disease or disorder are ameliorated or otherwisebeneficially altered. Treatment also encompasses any pharmaceutical useof the compositions herein, such as use for treating a cancer.

As used herein, amelioration of the symptoms of a particular disorder byadministration of a particular compound or pharmaceutical compositionrefers to any lessening, whether permanent or temporary, lasting ortransient that can be attributed to or associated with administration ofthe composition.

As used herein, the abbreviations for any protective groups, amino acidsand other compounds, are, unless indicated otherwise, in accord withtheir common usage, recognized abbreviations, or the IUPAC-IUBCommission on Biochemical Nomenclature (see, (1972) Biochem.11:942-944).

B. Compounds

Provided herein are benzo-lipoxin analogues having the general structure1

wherein:

-   -   A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino        or —OM, where M is a cation selected from the group consisting        of ammonium, tetra-alkyl ammonium, and the cations of sodium,        potassium, magnesium and zinc;    -   W is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo,        hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino,        dialkylamino, acylamino, carboxamido, or sulfonamide;    -   R^(a)-R^(c) are independently selected from a group costing of        hydrogen, alkyl, aryl, acyl or alkoxyacyl;    -   the integer n is zero, one or two;    -   the integer m is one or two;

and wherein the two substituents on the ring X are either ortho-, meta-or para-.

In certain embodiments herein, W is alkyl or aryloxy. In otherembodiments, W is butyl. In other embodiments, W is aryloxy.

In certain embodiments herein, A is hydroxy or alkoxy.

Some preferred embodiments of the present invention are benzo-lipoxinanalogues having one of the general structures 2-7,

wherein:

-   -   A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino        or —OM, where M is a cation selected from the group consisting        of ammonium, tetra-alkyl ammonium, and the cations of sodium,        potassium, magnesium and zinc;    -   W is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo,        hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino,        dialkylamino, acylamino, carboxamido, or sulfonamide;    -   R^(a)-R^(c) are independently selected from a group costing of        hydrogen, alkyl, aryl, acyl or alkoxyacyl;    -   the integer n is zero, one or two;    -   the integer m is one or two.

Additional preferred embodiments of the present invention are analogs oflipoxin A4 and have the stereochemistry designated in formulas 8-13.

wherein:

-   -   A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino        or —OM, where M is a cation selected from the group consisting        of ammonium, tetra-alkyl ammonium, and the cations of sodium,        potassium, magnesium and zinc;    -   W is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo,        hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino,        dialkylamino, acylamino, carboxamido, or sulfonamide;    -   R^(a)-R^(c) are independently selected from a group costing of        hydrogen, alkyl, aryl, acyl or alkoxyacyl;    -   the integer n is zero, one or two;    -   the integer m is one or two.

Additional preferred embodiments of the present invention are analogs of15-epi-lipoxin A4 and have the stereochemistry designated in formulas14-19.

wherein:

-   -   A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino        or —OM, where M is a cation selected from the group consisting        of ammonium, tetra-alkyl ammonium, and the cations of sodium,        potassium, magnesium and zinc;    -   W is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo,        hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino,        dialkylamino, acylamino, carboxamido, or sulfonamide;    -   R^(a)-R^(c) are independently selected from a group costing of        hydrogen, alkyl, aryl, acyl or alkoxyacyl;    -   the integer n is zero, one or two;    -   the integer m is one or two.

C. Preparation of the Compounds

The benzo lipoxin compounds provided herein are prepared as describedherein. In certain embodiments, benzo lipoxin compounds of the generalformula 1 can be prepared according to Scheme 1.

A common theme in the synthetic approach to these compounds is the useof iterative metal-mediated couplings of suitable intermediates (Scheme1).

wherein:

-   -   G, Q, X and Y are independently selected from a group consisting        of bromo, chloro, iodo, triflyl, diazonium, iodonium, boronic        acid, boronate, borinate, borate, trifluoroborate, stannyl,        perfluorostannyl, silyl, zinc, magnesium or copper.    -   Compound 20 is first reacted with either 21 or 22 followed by        reaction with the other, in the presence of a Pd, Ni or Cu        catalyst, provided that in each case appropriate combinations of        G, Q, X and Y are present in the reacting compounds.    -   Appropriate reaction combinations among 20+21 or 20+22 involve        the combination of compound 20 having G or C selected from a        group consisting of: bromo, chloro, iodo, triflyl, diazonium,        iodonium and a compound 21 or 22 having X and Y independently        selected from a group consisting of boronate, borinate, borate,        trifluoroborate, stannyl, perfluorostannyl, silyl, zinc,        magnesium or copper.    -   The coupling reactions among 20, 21 and 22 can also be carried        out in sequence or in one pot. In particular embodiments,        compounds 20, 21 and 22 can also be connected to a polymeric        chain or other solid phase material.

D. Formulation of Pharmaceutical Compositions

The pharmaceutical compositions provided herein contain therapeuticallyeffective amounts of one or more of compounds provided herein in apharmaceutically acceptable carrier.

The compositions contain one or more compounds provided herein. Thecompounds are preferably formulated into suitable pharmaceuticalpreparations such as solutions, suspensions, tablets, dispersibletablets, pills, capsules, powders, sustained release formulations orelixirs, for oral administration or in sterile solutions or suspensionsfor parenteral administration, as well as transdermal patch preparationand dry powder inhalers. Typically the compounds described above areformulated into pharmaceutical compositions using techniques andprocedures well known in the art (see, e.g., Ansel Introduction toPharmaceutical Dosage Forms, Fourth Edition 1985, 126).

In the compositions, effective concentrations of one or more compoundsor pharmaceutically acceptable derivatives is (are) mixed with asuitable pharmaceutical carrier or vehicle. The compounds may bederivatized as the corresponding salts, esters, enol ethers or esters,acids, bases, solvates, hydrates or prodrugs prior to formulation, asdescribed above. The concentrations of the compounds in the compositionsare effective for delivery of an amount, upon administration, thattreats, prevents, or ameliorates one or more of the symptoms ofconditions including, but not limited to, undesired cell proliferation,coronary restenosis, osteoporosis and syndromes characterized by chronicinflammation, autoimmune diseases and cardiovascular diseases.

Typically, the compositions are formulated for single dosageadministration. To formulate a composition, the weight fraction ofcompound is dissolved, suspended, dispersed or otherwise mixed in aselected vehicle at an effective concentration such that the treatedcondition is relieved or ameliorated. Pharmaceutical carriers orvehicles suitable for administration of the compounds provided hereininclude any such carriers known to those skilled in the art to besuitable for the particular mode of administration.

In addition, the compounds may be formulated as the solepharmaceutically active ingredient in the composition or may be combinedwith other active ingredients. Liposomal suspensions, includingtissue-targeted liposomes, such as tumor-targeted liposomes, may also besuitable as pharmaceutically acceptable carriers. These may be preparedaccording to methods known to those skilled in the art. For example,liposome formulations may be prepared as described in U.S. Pat. No.4,522,811. Briefly, liposomes such as multilamellar vesicles (MLV's) maybe formed by drying down egg phosphatidyl choline and brain phosphatidylserine (7:3 molar ratio) on the inside of a flask. A solution of acompound provided herein in phosphate buffered saline lacking divalentcations (PBS) is added and the flask shaken until the lipid film isdispersed. The resulting vesicles are washed to remove unencapsulatedcompound, pelleted by centrifugation, and then resuspended in PBS.

The active compound is included in the pharmaceutically acceptablecarrier in an amount sufficient to exert a therapeutically useful effectin the absence of undesirable side effects on the patient treated. Thetherapeutically effective concentration may be determined empirically bytesting the compounds in in vitro and in vivo systems described hereinand then extrapolated therefrom for dosages for humans.

The concentration of active compound in the pharmaceutical compositionwill depend on absorption, inactivation and excretion rates of theactive compound, the physicochemical characteristics of the compound,the dosage schedule, and amount administered as well as other factorsknown to those of skill in the art. For example, the amount that isdelivered is sufficient to ameliorate one or more of the symptoms ofdiseases or disorders associated undesired cell proliferation, coronaryrestenosis, osteoporosis, syndromes characterized by chronicinflammation, autoimmune diseases and cardiovascular diseases asdescribed herein.

Typically a therapeutically effective dosage should produce a serumconcentration of active ingredient of from about 0.1 ng/ml to about50-100 μg/ml. The pharmaceutical compositions typically should provide adosage of from about 0.001 mg to about 2000 mg of compound per kilogramof body weight per day. Pharmaceutical dosage unit forms are prepared toprovide from about 1 mg to about 1000 mg and preferably from about 10 toabout 500 mg of the essential active ingredient or a combination ofessential ingredients per dosage unit form.

The active ingredient may be administered at once, or may be dividedinto a number of smaller doses to be administered at intervals of time.It is understood that the precise dosage and duration of treatment is afunction of the disease being treated and may be determined empiricallyusing known testing protocols or by extrapolation from in vivo or invitro test data. It is to be noted that concentrations and dosage valuesmay also vary with the severity of the condition to be alleviated. It isto be further understood that for any particular subject, specificdosage regimens should be adjusted over time according to the individualneed and the professional judgment of the person administering orsupervising the administration of the compositions, and that theconcentration ranges set forth herein are exemplary only and are notintended to limit the scope or practice of the claimed compositions.

Pharmaceutically acceptable derivatives include acids, bases, enolethers and esters, salts, esters, hydrates, solvates and prodrug forms.The derivative is selected such that its pharmacokinetic properties aresuperior to the corresponding neutral compound.

Thus, effective concentrations or amounts of one or more of thecompounds described herein or pharmaceutically acceptable derivativesthereof are mixed with a suitable pharmaceutical carrier or vehicle forsystemic, topical or local administration to form pharmaceuticalcompositions. Compounds are included in an amount effective forameliorating one or more symptoms of, or for treating or preventingdiseases or disorders associated with undesired cell proliferation,coronary restenosis, osteoporosis, syndromes characterized by chronicinflammation, autoimmune diseases and cardiovascular diseases asdescribed herein. The concentration of active compound in thecomposition will depend on absorption, inactivation, excretion rates ofthe active compound, the dosage schedule, amount administered,particular formulation as well as other factors known to those of skillin the art.

The compositions are intended to be administered by a suitable route,including orally, parenterally, rectally, topically and locally. Fororal administration, capsules and tablets are presently preferred. Thecompositions are in liquid, semi-liquid or solid form and are formulatedin a manner suitable for each route of administration. Preferred modesof administration include parenteral and oral modes of administration.Oral administration is presently most preferred.

Solutions or suspensions used for parenteral, intradermal, subcutaneous,or topical application can include any of the following components: asterile diluent, such as water for injection, saline solution, fixedoil, polyethylene glycol, glycerine, propylene glycol or other syntheticsolvent; antimicrobial agents, such as benzyl alcohol and methylparabens; antioxidants, such as ascorbic acid and sodium bisulfate;chelating agents, such as ethylenediaminetetraacetic acid (EDTA);buffers, such as acetates, citrates and phosphates; and agents for theadjustment of tonicity such as sodium chloride or dextrose. Parenteralpreparations can be enclosed in ampules, disposable syringes or singleor multiple dose vials made of glass, plastic or other suitablematerial.

In instances in which the compounds exhibit insufficient solubility,methods for solubilizing compounds may be used. Such methods are knownto those of skill in this art, and include, but are not limited to,using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants,such as TWEEN®, or dissolution in aqueous sodium bicarbonate.

Upon mixing or addition of the compound(s), the resulting mixture may bea solution, suspension, emulsion or the like. The form of the resultingmixture depends upon a number of factors, including the intended mode ofadministration and the solubility of the compound in the selectedcarrier or vehicle. The effective concentration is sufficient forameliorating the symptoms of the disease, disorder or condition treatedand may be empirically determined.

The pharmaceutical compositions are provided for administration tohumans and animals in unit dosage forms, such as tablets, capsules,pills, powders, granules, sterile parenteral solutions or suspensions,and oral solutions or suspensions, and oil-water emulsions containingsuitable quantities of the compounds or pharmaceutically acceptablederivatives thereof. The pharmaceutically therapeutically activecompounds and derivatives thereof are typically formulated andadministered in unit-dosage forms or multiple-dosage forms. Unit-doseforms as used herein refers to physically discrete units suitable forhuman and animal subjects and packaged individually as is known in theart. Each unit-dose contains a predetermined quantity of thetherapeutically active compound sufficient to produce the desiredtherapeutic effect, in association with the required pharmaceuticalcarrier, vehicle or diluent. Examples of unit-dose forms include ampulesand syringes and individually packaged tablets or capsules. Unit-doseforms may be administered in fractions or multiples thereof. Amultiple-dose form is a plurality of identical unit-dosage formspackaged in a single container to be administered in segregatedunit-dose form. Examples of multiple-dose forms include vials, bottlesof tablets or capsules or bottles of pints or gallons. Hence, multipledose form is a multiple of unit-doses which are not segregated inpackaging.

The composition can contain along with the active ingredient: a diluentsuch as lactose, sucrose, dicalcium phosphate, orcarboxymethylcellulose; a lubricant, such as magnesium stearate, calciumstearate and talc; and a binder such as starch, natural gums, such asgum acaciagelatin, glucose, molasses, polvinylpyrrolidine, cellulosesand derivatives thereof, povidone, crospovidones and other such bindersknown to those of skill in the art. Liquid pharmaceuticallyadministrable compositions can, for example, be prepared by dissolving,dispersing, or otherwise mixing an active compound as defined above andoptional pharmaceutical adjuvants in a carrier, such as, for example,water, saline, aqueous dextrose, glycerol, glycols, ethanol, and thelike, to thereby form a solution or suspension. If desired, thepharmaceutical composition to be administered may also contain minoramounts of nontoxic auxiliary substances such as wetting agents,emulsifying agents, or solubilizing agents, pH buffering agents and thelike, for example, acetate, sodium citrate, cyclodextrine derivatives,sorbitan monolaurate, triethanolamine sodium acetate, triethanolamineoleate, and other such agents. Actual methods of preparing such dosageforms are known, or will be apparent, to those skilled in this art; forexample, see Remington's Pharmaceutical Sciences, Mack PublishingCompany, Easton, Pa., 15th Edition, 1975. The composition or formulationto be administered will, in any event, contain a quantity of the activecompound in an amount sufficient to alleviate the symptoms of thetreated subject.

Dosage forms or compositions containing active ingredient in the rangeof 0.005% to 100% with the balance made up from non-toxic carrier may beprepared. For oral administration, a pharmaceutically acceptablenon-toxic composition is formed by the incorporation of any of thenormally employed excipients, such as, for example pharmaceutical gradesof mannitol, lactose, starch, magnesium stearate, talcum, cellulosederivatives, sodium crosscarmellose, glucose, sucrose, magnesiumcarbonate or sodium saccharin. Such compositions include solutions,suspensions, tablets, capsules, powders and sustained releaseformulations, such as, but not limited to, implants andmicroencapsulated delivery systems, and biodegradable, biocompatiblepolymers, such as collagen, ethylene vinyl acetate, polyanhydrides,polyglycolic acid, polyorthoesters, polylactic acid and others. Methodsfor preparation of these compositions are known to those skilled in theart. The contemplated compositions may contain 0.001%-100% activeingredient, preferably 0.1-85%, typically 75-95%.

The active compounds or pharmaceutically acceptable derivatives may beprepared with carriers that protect the compound against rapidelimination from the body, such as time release formulations orcoatings.

The compositions may include other active compounds to obtain desiredcombinations of properties. The compounds provided herein, orpharmaceutically acceptable derivatives thereof as described herein, mayalso be advantageously administered for therapeutic or prophylacticpurposes together with another pharmacological agent known in thegeneral art to be of value in treating one or more of the diseases ormedical conditions referred to hereinabove, such as diseases ordisorders associated with undesired cell proliferation, coronaryrestenosis, osteoporosis, syndromes characterized by chronicinflammation, autoimmune diseases and cardiovascular diseases. It is tobe understood that such combination therapy constitutes a further aspectof the compositions and methods of treatment provided herein.

1. Compositions for Oral Administration

Oral pharmaceutical dosage forms are either solid, gel or liquid. Thesolid dosage forms are tablets, capsules, granules, and bulk powders.Types of oral tablets include compressed, chewable lozenges and tabletswhich may be enteric-coated, sugar-coated or film-coated. Capsules maybe hard or soft gelatin capsules, while granules and powders may beprovided in non-effervescent or effervescent form with the combinationof other ingredients known to those skilled in the art.

In certain embodiments, the formulations are solid dosage forms,preferably capsules or tablets. The tablets, pills, capsules, trochesand the like can contain any of the following ingredients, or compoundsof a similar nature: a binder; a diluent; a disintegrating agent; alubricant; a glidant; a sweetening agent; and a flavoring agent.

Examples of binders include microcrystalline cellulose, gum tragacanth,glucose solution, acacia mucilage, gelatin solution, sucrose and starchpaste. Lubricants include talc, starch, magnesium or calcium stearate,lycopodium and stearic acid. Diluents include, for example, lactose,sucrose, starch, kaolin, salt, mannitol and dicalcium phosphate.Glidants include, but are not limited to, colloidal silicon dioxide.Disintegrating agents include crosscarmellose sodium, sodium starchglycolate, alginic acid, corn starch, potato starch, bentonite,methylcellulose, agar and carboxymethylcellulose. Coloring agentsinclude, for example, any of the approved certified water soluble FD andC dyes, mixtures thereof; and water insoluble FD and C dyes suspended onalumina hydrate. Sweetening agents include sucrose, lactose, mannitoland artificial sweetening agents such as saccharin, and any number ofspray dried flavors. Flavoring agents include natural flavors extractedfrom plants such as fruits and synthetic blends of compounds whichproduce a pleasant sensation, such as, but not limited to peppermint andmethyl salicylate. Wetting agents include propylene glycol monostearate,sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylenelaural ether. Emetic-coatings include fatty acids, fats, waxes, shellac,ammoniated shellac and cellulose acetate phthalates. Film coatingsinclude hydroxyethylcellulose, sodium carboxymethylcellulose,polyethylene glycol 4000 and cellulose acetate phthalate.

If oral administration is desired, the compound could be provided in acomposition that protects it from the acidic environment of the stomach.For example, the composition can be formulated in an enteric coatingthat maintains its integrity in the stomach and releases the activecompound in the intestine. The composition may also be formulated incombination with an antacid or other such ingredient.

When the dosage unit form is a capsule, it can contain, in addition tomaterial of the above type, a liquid carrier such as a fatty oil. Inaddition, dosage unit forms can contain various other materials whichmodify the physical form of the dosage unit, for example, coatings ofsugar and other enteric agents. The compounds can also be administeredas a component of an elixir, suspension, syrup, wafer, sprinkle, chewinggum or the like. A syrup may contain, in addition to the activecompounds, sucrose as a sweetening agent and certain preservatives, dyesand colorings and flavors.

The active materials can also be mixed with other active materials whichdo not impair the desired action, or with materials that supplement thedesired action, such as antacids, H2 blockers, and diuretics. The activeingredient is a compound or pharmaceutically acceptable derivativethereof as described herein. Higher concentrations, up to about 98% byweight of the active ingredient may be included.

Pharmaceutically acceptable carriers included in tablets are binders,lubricants, diluents, disintegrating agents, coloring agents, flavoringagents, and wetting agents. Enteric-coated tablets, because of theenteric-coating, resist the action of stomach acid and dissolve ordisintegrate in the neutral or alkaline intestines. Sugar-coated tabletsare compressed tablets to which different layers of pharmaceuticallyacceptable substances are applied. Film-coated tablets are compressedtablets which have been coated with a polymer or other suitable coating.Multiple compressed tablets are compressed tablets made by more than onecompression cycle utilizing the pharmaceutically acceptable substancespreviously mentioned. Coloring agents may also be used in the abovedosage forms. Flavoring and sweetening agents are used in compressedtablets, sugar-coated, multiple compressed and chewable tablets.Flavoring and sweetening agents are especially useful in the formationof chewable tablets and lozenges.

Liquid oral dosage forms include aqueous solutions, emulsions,suspensions, solutions and/or suspensions reconstituted fromnon-effervescent granules and effervescent preparations reconstitutedfrom effervescent granules. Aqueous solutions include, for example,elixirs and syrups. Emulsions are either oil-in-water or water-in-oil.

Elixirs are clear, sweetened, hydroalcoholic preparations.Pharmaceutically acceptable carriers used in elixirs include solvents.Syrups are concentrated aqueous solutions of a sugar, for example,sucrose, and may contain a preservative. An emulsion is a two-phasesystem in which one liquid is dispersed in the form of small globulesthroughout another liquid. Pharmaceutically acceptable carriers used inemulsions are non-aqueous liquids, emulsifying agents and preservatives.Suspensions use pharmaceutically acceptable suspending agents andpreservatives. Pharmaceutically acceptable substances used innon-effervescent granules, to be reconstituted into a liquid oral dosageform, include diluents, sweeteners and wetting agents. Pharmaceuticallyacceptable substances used in effervescent granules, to be reconstitutedinto a liquid oral dosage form, include organic acids and a source ofcarbon dioxide. Coloring and flavoring agents are used in all of theabove dosage forms.

Solvents include glycerin, sorbitol, ethyl alcohol and syrup. Examplesof preservatives include glycerin, methyl and propylparaben, benzoicadd, sodium benzoate and alcohol. Examples of non-aqueous liquidsutilized in emulsions include mineral oil and cottonseed oil. Examplesof emulsifying agents include gelatin, acacia, tragacanth, bentonite,and surfactants such as polyoxyethylene sorbitan monooleate. Suspendingagents include sodium carboxymethylcellulose, pectin, tragacanth, Veegumand acacia. Diluents include lactose and sucrose. Sweetening agentsinclude sucrose, syrups, glycerin and artificial sweetening agents suchas saccharin. Wetting agents include propylene glycol monostearate,sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylenelauryl ether. Organic adds include citric and tartaric acid. Sources ofcarbon dioxide include sodium bicarbonate and sodium carbonate. Coloringagents include any of the approved certified water soluble FD and Cdyes, and mixtures thereof. Flavoring agents include natural flavorsextracted from plants such fruits, and synthetic blends of compoundswhich produce a pleasant taste sensation.

For a solid dosage form, the solution or suspension, in for examplepropylene carbonate, vegetable oils or triglycerides, is preferablyencapsulated in a gelatin capsule. Such solutions, and the preparationand encapsulation thereof, are disclosed in U.S. Pat. Nos. 4,328,245;4,409,239; and 4,410,545. For a liquid dosage form, the solution, e.g.,for example, in a polyethylene glycol, may be diluted with a sufficientquantity of a pharmaceutically acceptable liquid carrier, e.g., water,to be easily measured for administration.

Alternatively, liquid or semi-solid oral formulations may be prepared bydissolving or dispersing the active compound or salt in vegetable oils,glycols, triglycerides, propylene glycol esters (e.g., propylenecarbonate) and other such carriers, and encapsulating these solutions orsuspensions in hard or soft gelatin capsule shells. Other usefulformulations include those set forth in U.S. Pat. Nos. Re 28,819 and4,358,603. Briefly, such formulations include, but are not limited to,those containing a compound provided herein, a dialkylated mono- orpolyalkylene glycol, including, but not limited to,1,2-dimethoxymethane, diglyme, triglyme, tetraglyme, polyethyleneglycol-350-dimethyl ether, polyethylene glycol-550-dimethyl ether,polyethylene glycol-750-dimethyl ether wherein 350, 550 and 750 refer tothe approximate average molecular weight of the polyethylene glycol, andone or more antioxidants, such as butylated hydroxytoluene (BHT),butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone,hydroxycoumarins, ethanolamine, lecithin, cephalin, ascorbic acid, malicacid, sorbitol, phosphoric acid, thiodipropionic acid and its esters,and dithiocarbamates.

Other formulations include, but are not limited to, aqueous alcoholicsolutions including a pharmaceutically acceptable acetal. Alcohols usedin these formulations are any pharmaceutically acceptable water-misciblesolvents having one or more hydroxyl groups, including, but not limitedto, propylene glycol and ethanol. Acetals include, but are not limitedto, di(lower alkyl) acetals of lower alkyl aldehydes such asacetaldehyde diethyl acetal.

In all embodiments, tablets and capsules formulations may be coated asknown by those of skill in the art in order to modify or sustaindissolution of the active ingredient. Thus, for example, they may becoated with a conventional enterically digestible coating, such asphenylsalicylate, waxes and cellulose acetate phthalate.

2. Injectables, Solutions and Emulsions

Parenteral administration, generally characterized by injection, eithersubcutaneously, intramuscularly or intravenously is also contemplatedherein. Injectables can be prepared in conventional forms, either asliquid solutions or suspensions, solid forms suitable for solution orsuspension in liquid prior to injection, or as emulsions. Suitableexcipients are, for example, water, saline, dextrose, glycerol orethanol. In addition, if desired, the pharmaceutical compositions to beadministered may also contain minor amounts of non-toxic auxiliarysubstances such as wetting or emulsifying agents, pH buffering agents,stabilizers, solubility enhancers, and other such agents, such as forexample, sodium acetate, sorbitan monolaurate, triethanolamine oleateand cyclodextrins. Implantation of a slow-release or sustained-releasesystem, such that a constant level of dosage is maintained (see, e.g.,U.S. Pat. No. 3,710,795) is also contemplated herein. Briefly, acompound provided herein is dispersed in a solid inner matrix, e.g.,polymethylmethacrylate, polybutylmethacrylate, plasticized orunplasticized polyvinylchloride, plasticized nylon, plasticizedpolyethyleneterephthalate, natural rubber, polyisoprene,polyisobutylene, polybutadiene, polyethylene, ethylene-vinylacetatecopolymers, silicone rubbers, polydimethylsiloxanes, silicone carbonatecopolymers, hydrophilic polymers such as hydrogels of esters of acrylicand methacrylic acid, collagen, cross-linked polyvinylalcohol andcross-linked partially hydrolyzed polyvinyl acetate, that is surroundedby an outer polymeric membrane, e.g., polyethylene, polypropylene,ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers,ethylene/vinylacetate copolymers, silicone rubbers, polydimethylsiloxanes, neoprene rubber, chlorinated polyethylene, polyvinylchloride,vinylchloride copolymers with vinyl acetate, vinylidene chloride,ethylene and propylene, ionomer polyethylene terephthalate, butyl rubberepichlorohydrin rubbers, ethylene/vinyl alcohol copolymer,ethylene/vinyl acetate/vinyl alcohol terpolymer, andethylene/vinyloxyethanol copolymer, that is insoluble in body fluids.The compound diffuses through the outer polymeric membrane in a releaserate controlling step. The percentage of active compound contained insuch parenteral compositions is highly dependent on the specific naturethereof, as well as the activity of the compound and the needs of thesubject.

Parenteral administration of the compositions includes intravenous,subcutaneous and intramuscular administrations. Preparations forparenteral administration include sterile solutions ready for injection,sterile dry soluble products, such as lyophilized powders, ready to becombined with a solvent just prior to use, including hypodermic tablets,sterile suspensions ready for injection, sterile dry insoluble productsready to be combined with a vehicle just prior to use and sterileemulsions. The solutions may be either aqueous or nonaqueous.

If administered intravenously, suitable carriers include physiologicalsaline or phosphate buffered saline (PBS), and solutions containingthickening and solubilizing agents, such as glucose, polyethyleneglycol, and polypropylene glycol and mixtures thereof.

Pharmaceutically acceptable carriers used in parenteral preparationsinclude aqueous vehicles, nonaqueous vehicles, antimicrobial agents,isotonic agents, buffers, antioxidants, local anesthetics, suspendingand dispersing agents, emulsifying agents, sequestering or chelatingagents and other pharmaceutically acceptable substances.

Examples of aqueous vehicles include Sodium Chloride Injection, RingersInjection, Isotonic Dextrose Injection, Sterile Water Injection,Dextrose and Lactated Ringers Injection. Nonaqueous parenteral vehiclesinclude fixed oils of vegetable origin, cottonseed oil, corn oil, sesameoil and peanut oil. Antimicrobial agents in bacteriostatic orfungistatic concentrations must be added to parenteral preparationspackaged in multiple-dose containers which include phenols or cresols,mercurials, benzyl alcohol, chlorobutanol, methyl and propylp-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride andbenzethonium chloride. Isotonic agents include sodium chloride anddextrose. Buffers include phosphate and citrate. Antioxidants includesodium bisulfate. Local anesthetics include procaine hydrochloride.Suspending and dispersing agents include sodium carboxymethylcelluose,hydroxypropyl methylcellulose and polyvinylpyrrolidone. Emulsifyingagents include Polysorbate 80 (TWEEN® 80). A sequestering or chelatingagent of metal ions include EDTA. Pharmaceutical carriers also includeethyl alcohol, polyethylene glycol and propylene glycol for watermiscible vehicles and sodium hydroxide, hydrochloric acid, citric acidor lactic acid for pH adjustment.

The concentration of the pharmaceutically active compound is adjusted sothat an injection provides an effective amount to produce the desiredpharmacological effect. The exact dose depends on the age, weight andcondition of the patient or animal as is known in the art.

The unit-dose parenteral preparations are packaged in an ampule, a vialor a syringe with a needle. All preparations for parenteraladministration must be sterile, as is known and practiced in the art.

Illustratively, intravenous or intraarterial infusion of a sterileaqueous solution containing an active compound is an effective mode ofadministration. Another embodiment is a sterile aqueous or oily solutionor suspension containing an active material injected as necessary toproduce the desired pharmacological effect.

Injectables are designed for local and systemic administration.Typically a therapeutically effective dosage is formulated to contain aconcentration of at least about 0.1% w/w up to about 90% w/w or more,preferably more than 1% w/w of the active compound to the treatedtissue(s). The active ingredient may be administered at once, or may bedivided into a number of smaller doses to be administered at intervalsof time. It is understood that the precise dosage and duration oftreatment is a function of the tissue being treated and may bedetermined empirically using known testing protocols or by extrapolationfrom in vivo or in vitro test data. It is to be noted thatconcentrations and dosage values may also vary with the age of theindividual treated. It is to be further understood that for anyparticular subject, specific dosage regimens should be adjusted overtime according to the individual need and the professional judgment ofthe person administering or supervising the administration of theformulations, and that the concentration ranges set forth herein areexemplary only and are not intended to limit the scope or practice ofthe claimed formulations.

The compound may be suspended in micronized or other suitable form ormay be derivatized to produce a more soluble active product or toproduce a prodrug. The form of the resulting mixture depends upon anumber of factors, including the intended mode of administration and thesolubility of the compound in the selected carrier or vehicle. Theeffective concentration is sufficient for ameliorating the symptoms ofthe condition and may be empirically determined.

3. Lyophilized Powders

Of interest herein are also lyophilized powders, which can bereconstituted for administration as solutions, emulsions and othermixtures. They may also be reconstituted and formulated as solids orgels.

The sterile, lyophilized powder is prepared by dissolving a compoundprovided herein, or a pharmaceutically acceptable derivative thereof, ina suitable solvent. The solvent may contain an excipient which improvesthe stability or other pharmacological component of the powder orreconstituted solution, prepared from the powder. Excipients that may beused include, but are not limited to, dextrose, sorbital, fructose, cornsyrup, xylitol, glycerin, glucose, sucrose or other suitable agent. Thesolvent may also contain a buffer, such as citrate, sodium or potassiumphosphate or other such buffer known to those of skill in the art at,typically, about neutral pH. Subsequent sterile filtration of thesolution followed by lyophilization under standard conditions known tothose of skill in the art provides the desired formulation. Generally,the resulting solution will be apportioned into vials forlyophilization. Each vial will contain a single dosage (10-1000 mg,preferably 100-500 mg) or multiple dosages of the compound. Thelyophilized powder can be stored under appropriate conditions, such asat about 4° C. to room temperature.

Reconstitution of this lyophilized powder with water for injectionprovides a formulation for use in parenteral administration. Forreconstitution, about 1-50 mg, preferably 5-35 mg, more preferably about9-30 mg of lyophilized powder, is added per mL of sterile water or othersuitable carrier. The precise amount depends upon the selected compound.Such amount can be empirically determined.

4. Topical Administration

Topical mixtures are prepared as described for the local and systemicadministration. The resulting mixture may be a solution, suspension,emulsions or the like and are formulated as creams, gels, ointments,emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes,foams, aerosols, irrigations, sprays, suppositories, bandages, dermalpatches or any other formulations suitable for topical administration.

The compounds or pharmaceutically acceptable derivatives thereof may beformulated as aerosols for topical application, such as by inhalation(see, e.g., U.S. Pat. Nos. 4,044,126, 4,414,209, and 4,364,923, whichdescribe aerosols for delivery of a steroid useful for treatment ofinflammatory diseases, particularly asthma). These formulations foradministration to the respiratory tract can be in the form of an aerosolor solution for a nebulizer, or as a microfine powder for insufflation,alone or in combination with an inert carrier such as lactose. In such acase, the particles of the formulation will typically have diameters ofless than 50 microns, preferably less than 10 microns.

The compounds may be formulated for local or topical application, suchas for topical application to the skin and mucous membranes, such as inthe eye, in the form of gels, creams, and lotions and for application tothe eye or for intracisternal or intraspinal application. Topicaladministration is contemplated for transdermal delivery and also foradministration to the eyes or mucosa, or for inhalation therapies. Nasalsolutions of the active compound alone or in combination with otherpharmaceutically acceptable excipients can also be administered.

These solutions, particularly those intended for ophthalmic use, may beformulated as 0.01%-10% isotonic solutions, pH about 5-7, withappropriate salts.

5. Compositions for Other Routes of Administration

Other routes of administration, such as topical application, transdermalpatches, and rectal administration are also contemplated herein.

For example, pharmaceutical dosage forms for rectal administration arerectal suppositories, capsules and tablets for systemic effect. Rectalsuppositories are used herein mean solid bodies for insertion into therectum which melt or soften at body temperature releasing one or morepharmacologically or therapeutically active ingredients.Pharmaceutically acceptable substances utilized in rectal suppositoriesare bases or vehicles and agents to raise the melting point. Examples ofbases include cocoa butter (theobroma oil), glycerin-gelatin, carbowax(polyoxyethylene glycol) and appropriate mixtures of mono-, di- andtriglycerides of fatty acids. Combinations of the various bases may beused. Agents to raise the melting point of suppositories includespermaceti and wax. Rectal suppositories may be prepared either by thecompressed method or by molding. The typical weight of a rectalsuppository is about 2 to 3 gm.

Tablets and capsules for rectal administration are manufactured usingthe same pharmaceutically acceptable substance and by the same methodsas for formulations for oral administration.

6. Articles of Manufacture

The compounds or pharmaceutically acceptable derivatives thereof can bepackaged as articles of manufacture containing packaging material, acompound or pharmaceutically acceptable derivative thereof providedherein, which is used for treatment, prevention or amelioration of oneor more symptoms associated with undesired cell proliferation, coronaryrestenosis, osteoporosis, syndromes characterized by chronicinflammation, autoimmune diseases and cardiovascular diseases condition,and a label that indicates that the compound or pharmaceuticallyacceptable derivative thereof is used for treatment, prevention oramelioration of one or more symptoms associated with undesired cellproliferation, coronary restenosis, osteoporosis, syndromescharacterized by chronic inflammation, autoimmune diseases andcardiovascular diseases.

The articles of manufacture provided herein contain packaging materials.Packaging materials for use in packaging pharmaceutical products arewell known to those of skill in the art. See, e.g., U.S. Pat. Nos.5,323,907, 5,052,558 and 5,033,252. Examples of pharmaceutical packagingmaterials include, but are not limited to, blister packs, bottles,tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, andany packaging material suitable for a selected formulation and intendedmode of administration and treatment. A wide array of formulations ofthe compounds and compositions provided herein are contemplated as are avariety of treatments for any disorder associated with undesired cellproliferation, coronary restenosis, osteoporosis, syndromescharacterized by chronic inflammation, autoimmune diseases andcardiovascular diseases condition.

E. Methods of Use of the Compounds and Compositions

The compounds of the invention are structural analogs ofnaturally-occurring molecules that are known to have biological activityagainst a wide variety of targets, including diseases or conditionsassociated with inflammation or inflammatory response, undesired cellproliferation, such as cancer, and cardiovascular diseases. As such, thecompounds of the invention are expected to have similar activity againstthose targets.

Accordingly, in one aspect the invention features methods ofameliorating or treating diseases or conditions associated withinflammation or inflammatory response, involving the administration to asubject of a therapeutically effective amount of a compound or compoundsof the invention, such that inflammation or an inflammatory response aresignificantly reduced or eliminated in the subject. A significantreduction includes the reduction or elimination of a symptom or symptomsassociated with the inflammation or inflammatory response.

In another aspect, the invention features methods of ameliorating ortreating diseases or conditions associated with undesired cellproliferation, such as cancer, involving the administration to a subjectof an effective amount of a compound or compounds of the invention. Ingeneral, an effective amount is an amount sufficient to ensure adequateexposure of a target cell population, such that abnormal cellproliferation is substantially slowed or halted. A target population isa population of cells undergoing abnormal cell proliferation, such ascancerous and/or tumorous growth.

The invention will be further described in the following examples, whichare illustrative only, and which are not intended to limit the scope ofthe invention described in the claims.

EXAMPLES

In the following examples, efforts have been made to ensure accuracywith respect to numbers used (e.g. amounts, temperature, etc.) but someexperimental errors and deviations should be accounted for. Unlessindicated otherwise, parts are parts by weight, molecular weight isweight average molecular weight, temperature is in degrees centigrade,and pressure is at or near atmospheric. Starting materials used in theseexamples are generally either commercially available or can be readilyprepared from commercially available reagents by a procedure involvingone or more steps.

The following Schemes show examples of the synthesis of several benzolipoxin analogs. A common building block, compound 23 is preparedaccording to Scheme 2, while Schemes 3-6 outline the synthesis ofselected example of benzo-lipoxin analogues.

Example 1 (5S,6R,E)-methyl5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl)phenyl)oct-7-enoate

Step 1:

A solution of (5S,6S)-methyl5,6-bis(tert-butyldimethylsilyloxy)-7-oxoheptanoate (389 mg, 0.929 mmol)and iodoform (2.19 g, 5.57 mmol) in THF (20 mL) was allowed it to stirfor about 10 min. In a separate round bottom flask added chromiumchloride (II) (1.36 mg, 11.1 mmol) and dissolved it in THF (10 mL) andcooled the reaction mixture to 0° C. The aldehyde and iodoform mixturewere transferred to a stirring solution of chromium chloride at 0° C.,warmed to room temperature and allowed to stir for 3 h. The reaction wasquenched with water, extracted with ether, dried, and concentrated.Purification by flash chromatography (silica gel, hexanes) afforded 200mg (40% yield) of (5S,6R,E)-methyl5,6-bis(tert-butyldimethylsilyloxy)-8-iodooct-7-enoate. ¹H NMR (250 MHz,CDCl₃): δ 6.46 (dd, J=14.9 Hz, J=7.2 Hz 1H), 6.18 (d, J=15.4 Hz, 1H),3.85 (m, 1H), 3.63 (s, 3H), 3.52 (m, 1H), 2.27 (t, J=7.1 Hz, 3H), 1.62(m, 2H), 1.47 (m, 2H), 0.850 (s, 9H), 0.849 (s, 9H), 0.023 (s, 6H),0.013 (s, 3H), −0.005 (s, 3H).

Step 2:

The product from Step 1 (64 mg, 0.127 mmol), was placed in a microwavetube together with commercially available 2-bromo phenyl boronic acid(27 mg, 0.129 mmol), potassium carbonate (51 mg, 0.372 mmol), Pd(PPh₃)₄(7 mg, 5 mol %), and dioxane (1.5 mL). The tube was sealed, degassed,purged with argon, and heated to 60° C. The reaction mixture was stirredfor 12 h, after which time it was quenched with saturated ammoniumchloride, extracted with ether, dried, and concentrated. The product waspurified by preparatory TLC (silica plate, 8% ethyl acetate/hexanes) toafford 50 mg (70%) of (5S,6R,E)-methyl8-(2-bromophenyl)-5,6-bis(tert-butyldimethylsilyloxy)oct-7-enoate. 1HNMR (360 MHz, CDCl₃): δ 7.49 (dd, J=20 Hz, 7.7 Hz, 2H), 7.24 (t, J=8.3Hz, 1H), 7.06 (t, J=7.4 Hz, 1H), 6.84 (d, J=15.4 Hz, 1H), 6.10 (dd,J=15.9 Hz, 7.3 Hz), 4.48 (m, 1H), 3.63 (s, 3H), 2.29 (t, J=7.5 Hz), 1.71(m, 2H), 1.53 (m, 2H), 0.894 (s, 9H), 0.857 (s, 9H), 0.084 (s, 3H),0.080 (s, 6H), 0.016 (s, 3H). ¹³C NMR (500 MHz, CDCl₃): δ 136.90,136.61, 132.903, 129.93, 128.59, 127.42, 126.99, 77.0, 76.0, 50.9,34.35, 33.04, 29.70, 25.99, 20.67, 10.17, −3.95, −4.76.

Step 3:

Commercially available R-octyn-ol (146 mg, 0.611 mmol) was dissolved inDCM (4 mL), and cooled to 0° C., followed by addition of 2,6 lutidine(1.54 mg, 4.36 mmol) and tetra-butyldimethylsilyl-triflate (785 mg, 2.97mmol). The reaction mixture was allowed to stir overnight, quenched withwater, and extracted with ether. Flash chromatography (silica gel,hexanes) afforded 463 mg (90%) of the protected alcohol. To theprotected alcohol (146 mg, 0.611 mmol) was added catechol borane (73 mg,0.611 mmol) neat, heated to 60° C. and allowed to stir overnightgenerating (5S,6R,E)-methyl8-(2-bromophenyl)-5,6-bis(tert-butyldimethylsilyloxy)oct-7-enoate. ¹HNMR (250 MHz, CDCl₃): δ 7.37 (m, 1H), 7.21 (m, 2H), 7.11 (J, J=4.6 Hz,2H), 6.99 (m, 1H), 6.13 (dd, J=18 Hz, 1.8 Hz, 1H), 4.43 (s, 1H),1.75-1.63 (m, 2H), 1.58-1.35 (m, 6H), 1.08 (s, 3H), 1.03 (s, 9H), 0.239(s, 3H), 0.220 (s, 3H).

Step 4:

In a microwave tube added the product of Step 2 (35 mg, 0.070 mmol), theproduct of Step 3 (23 mg, 0.064 mmol), potassium carbonate (25 mg, 0.183mmol), Pd(PPh₃)₄ (3.5 mg, 5 mol %), and dioxane/water (1/3:2/3, 3 mL).The tube was sealed, degassed, purged with argon, heated to 80° C. andallowed to stir for 24 h. The reaction was quenched with saturatedammonium chloride, extracted with ether, dried and concentrated.Purification with prepatory TLC (silica plate, 5% ethyl acetate/hexane)afforded 18.2 mg (40%) of (5S,6R,E)-methyl5,6-bis(tert-butyldimethylsilyloxy)-8-(2-((R,E)-3-(tert-butyldimethylsilyloxy)oct-1-enyl)phenyl)oct-7-enoate.¹H NMR (360 MHz, CDCl₃): δ 7.37 (m, 2H), 7.19 (m, 2H), 6.72 (dd, J=15.3Hz, 3.4 Hz, 2H), 6.06-5.96 (m, 2H), 4.21 (m, 1H), 4.09 (m, 1H), 3.65 (m,1H), 3.61 (s, 3H), 2.27 (t, J=7.2 Hz, 2H), 1.75-1.60 (m, 4H), 1.54-1.44(m, 8H), 1.29-1.21 (m, 5H), 0.890 (s, 9H), 0.879 (s, 9H), 0.057 (s, 6H),0.031 (s, 3H), 0.019 (s, 3H), 0.008 (s, 3H), −0.004 (s, 3H). ¹³C (360MHz, CDCl₃): δ 173.94, 136.20, 135.54, 135.06, 132.63, 128.66, 127.46,127.34, 126.54, 126.48, 126.24, 77.45, 76.07, 73.87, 51.45, 38.46,34.35, 32.88, 31.85, 26.01, 25.00, 22.68, 14.09, −3.99, −4.78.

Step 5:

The product of Step 4 was dissolved in THF (1 mL) and cooled to 0° C.Tetra-butyl ammonium fluoride (10 μL, 0.078 mmol) was added and thereaction mixture was warmed to RT and allowed to stir overnight. Thereaction mixture was quenched with saturated ammonium chloride,extracted with ether, dried and concentrated. Purification bypreparatory TLC (silica plate, 5% MeOH/Ethyl acetate) afforded 6.1 mg(96.8%) of (5S,6R,E)-methyl5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl)phenyl)oct-7-enoate. ¹HNMR (250 Hz, CDCl₃): δ 7.38 (m, 2H), 7.22 (m, 2H), 6.86 (t, J=15.4 Hz,1H), 6.07 (m, 1H), 4.27 (m, 1H), 3.77 (m, 1H), 3.63 (m, 1H), 3.46 (q,J=14 Hz, 6.9 Hz, 1H), 2.35 (t, J=7.5 Hz, 2H), 1.81-1.53 (m, 4H),1.32-1.16 (m, 7H), 0.915-0.789 (m, 4H). ¹³C (500 NMR C₆D₆): δ 173.79,136.18, 136.12, 135.98, 131.59, 130.34, 136.18, 131.59, 130.34, 128.53,128.20, 127.81, 127.68, 127.62, 127.47, 127.13, 76.02, 74.36, 72.65,51.01, 37.92, 33.83, 32.22, 30.15, 25.58, 23.05, 21.57, 14.24.

Example 2 (5S,6R,E)-methyl5,6-dihydroxy-8-(3-((R,E)-3-hydroxyoct-1-enyl)phenyl)oct-7-enoate

Prepared similar to Example 1. ¹H NMR (250 MHz, CDCl₃): δ 7.46 (s, 1H),7.23 (m, 3H), 6.59 (dd, J=20 Hz, 15.7 Hz, 2H), 6.25 (m, 2H), 4.21 (m,1H), 3.75 (m, 1H), 3.64 (s, 3H), 3.45 (m, 1H), 2.35 (t, J=7.5 Hz, 2H),1.39-1.20 (m, 11H), 0.870 (m, 4H). ¹³C NMR (250 MHz, CDCl₃): δ 176.10.136.62, 136.62, 133.10, 133.03, 129.85, 128.86, 127.24, 126.08, 125.86,124.63, 75.88, 73.81, 73.08, 51.61, 37.36, 33.73, 31.79, 31.49, 29.71,25.13, 22.62, 21.09, 14.01.

Example 3 (5S,6R,E)-methyl5,6-dihydroxy-8-(2-((R,1E,3E)-5-hydroxydeca-1,3-dienyl)phenyl)oct-7-enoate

Prepared similar to Example 1. ¹H NMR (250 MHz, CDCl₃): δ 7.46-7.35 (m,2H), 7.29-7.17 (m, 2H), 7.10 (m, 1H), 6.87 (dd, J=29.9 Hz, 15.4 Hz, 1H),6.63 (m, 1H), 6.39 (m, 1H), 6.11 (dd, J=16.2 Hz, 7.2 Hz), 5.80 (dd,J=14.7 Hz, 6.7 Hz), 4.27 (m, 1H), 3.74 (m, 1H), 3.45 (m, 1H), 3.63 (s,3H), 2.32 (t, J=2.1 Hz, 2H), 1.34-1.20 (m, 8H), 0.902-0.820 (m, 6H). ¹³CNMR (500 MHz, CDCl₃): δ 172.11, 137.25, 135.48, 134.91, 130.73, 130.59,129.84, 129.79, 128.26, 127.92, 127.62, 126.86, 126.08, 75.91, 73.87,72.65, 51.62, 37.33, 33.79, 31.53, 29.69, 25.11, 22.59, 21.12, 13.98.

Example 4 (5S,6R,E)-methyl5,6-dihydroxy-8-(2-(1-hydroxyhexyl)phenyl)oct-7-enoate

Step 1.

Triethylamine (126 mg, 2.50 mmol) and O,N, dimethyl hydroxyl amine (304mg, 2.50 mmol) were dissolved in DCM and cooled to −10° C., after whichtime commercially available 2-bromobenzoyl chloride (500 mg, 2.27 mmol)was added, followed by addition of more TEA (126 mg, 2.50 mmol). Thereaction was warmed to RT and allowed to stir overnight. DCM wasremoved, diluted with ether, acidified with 1N HCl, neutralized withsaturated bicarbonate, extracted with ether, dried and collected. Theresulting amide was dissolved in THF, cooled to −78° C., followed byaddition of pentyl magnesium bromide (925 μL, 1.85 mmol), and allowed tostir for 90 min. The reaction was quenched with ammonium chloride,extracted with ether, dried and concentrated. Purification with flashchromatography (silica gel, 10% ethyl acetate/hexanes) afforded thedesired ketone in 70% yield (400 mg). ¹H NMR (250 MHz, CDCl₃): δ 8.0 (m,1H), 7.70 (dd, J=8 Hz, 2 Hz, 2H), 7.57-7.21 (m, 2H), 2.94 (t, J=7 Hz,2H), 1.72 (m, 2H), 1.34 (m, 2H), 1.21 (m, 2H), 0.892 (m, 3H).

Step 2.

The product of Step 1 (109 mg, 0.428 mmol) was dissolved in MeOH (5 mL)followed by addition of sodium borohydride (32 mg, 0.856 mmol). Thereaction mixture was allowed to stir for 1 hour, after which time it wasquenched with 1N HCl, extracted with ether, dried, and concentrated.Preparatory TLC (silica plate, 20% ethyl acetate/hexane) afforded thefree alcohol in (109 mg) 90% yield. The alcohol (109 mg, 0.428 mmol) wasdissolved in DCM (5 mL) and 2,6 lutidine (169 mg, 0.642 mmol), andtetra-butyldimethyl silyl triflate (100 mg, 0.940 mmol) were added andthe reaction mixture was stirred overnight. The reaction was quenchedwith saturated ammonium chloride, extracted with ether, dried andconcentrated. Preparatory TLC (silica plate, hexanes) afforded theprotected alcohol in (150 mg) 95% yield. ¹H NMR (360 MHz, CDCl₃): δ 7.57(dd, J=7.8 Hz, 2.2 Hz, 1H), 7.43 (dd, J=8.1 Hz, J=1.5 Hz, 1H), 7.19 (m,1H), 7.04 (m, 1H), 4.99 (m, 1H), 4.56 (m, 1H), 1.56 (m, 2H), 1.24 (m,6H), 0.868 (s, 9H), 0.846 (s, 3H), 0.023 (s, 3H).

Step 3.

In a microwave tube added the product of Step 2 (16 mg, 0.037 mmol),bispinacaloto diboron (10 mg, 0.42 mmol), potassium acetate (11 mg, 0.11mmol), PdCl₂(dppf) (1 mg, 3 mol %), dppf (1.25 mg, 6 mol %), and DMSO(226 μL) were added. The tube was sealed, degassed, purged with argon,and heated to 80° C. The reaction mixture was allowed to stir for 16 h,after which time the reaction was quenched with ammonium chloride,extracted with ether, dried and concentrated. Purification bypreparatory TLC (silica plate, 5% ethyl acetate/hexanes) afforded theboronic pinacol ester.

Step 4.

In a microwave tube added the product of Step 1 (Example 1) (5.7 mg,0.011 mmol), the product of Step 3 (5 mg, 0.11 mmol) (3.xx), potassiumphosphate (6.7 mg, 0.032 mmol), PdCl₂(dppf) (1 mg, 3 mol %), dppf (1.2mg, 6 mol %), and DMF (150 μL). The tube was sealed, degassed, purgedwith argon, and heated to 60° C. The reaction mixture was allowed tostir for 16 h, after which time it was quenched with saturated ammoniumchloride, extracted with ether, dried and concentrated. Purification bypreparatory TLC afforded 3.6 mg (45% yield) of (5S,6R,E)-methyl5,6-bis(tert-butyldimethylsilyloxy)-8-(2-(1-(tert-butyldimethylsilyloxy)hexyl)phenyl)oct-7-enoate.¹H NMR (250 MHz, CDCl₃): δ 7.45 (m, 1H), 7.35 (m, 1H), 7.16 (m, 2H),6.75 (m, 1H), 6.01 (m, 1H), 4.91 (m, 1H), 4.12 (m, 1H), 3.64 (s, 3H),2.22 (t, J=7.1 Hz, 2H), 1.64-1.45 (m, 4H), 1.31-1.12 (m, 11H), 0.911 (s,9H), 0.810 (s, 18H), 0.101 (s, 3H), 0.005 (s, 3H), −0.01 (s, 3H), −0.02(s, 3H), −0.199, (s, 3H), −0.201 (s, 3H).

Step 4.

Performed similarly to Step 5 (Example 1) to give (5S,6R,E)-methyl5,6-dihydroxy-8-(2-(1-hydroxyhexyl)phenyl)oct-7-enoate. ¹H NMR (500 MHz,CDCl₃): δ 7.46 (m, 2H), 7.31 (m, 2H), 7.04 (d, J=15 Hz, 1H), 6.13 (dd,J=16.3 Hz, 7.1 Hz, 1H), 4.99 (m, 1H), 4.30 (m, 1H), 3.79 (m, 1H), 3.67(m, 1H), 2.38 (m, 2H), 1.87 (m, 2H), 1.74 (m, 4H), 1.31 (m, 4H), 1.22(m, 3H). ¹³C NMR (500 MHz, CDCl₃): δ 172.11, 130.14, 128.27, 128.12,127.51, 126.54, 125.75, 77.20, 73.49, 71.09, 38.38, 31.71, 29.78, 25.67,22.58, 21.87, 18.80, 13.99.

It is understood that the foregoing detailed description andaccompanying examples are merely illustrative, and are not to be takenas limitations upon the scope of the subject matter. Various changes andmodifications to the disclosed embodiments will be apparent to thoseskilled in the art. Such changes and modifications, including withoutlimitation those relating to the chemical structures, substituents,derivatives, intermediates, syntheses, formulations and/or methods ofuse provided herein, may be made without departing from the spirit andscope thereof. U.S. patents and publications referenced herein areincorporated by reference.

The provided benzo lipoxin analogs exhibit anti-inflammatory propertiesin various inflammation models.

A number of embodiments of the invention have been described.Nevertheless, it will be understood that various modifications may bemade without departing from the spirit and scope of the invention.Accordingly, other embodiments are within the scope of the followingclaims.

What is claimed:
 1. A pharmaceutical composition comprising: (a) anactive agent comprising a compound having the structure of formula 1:

wherein: A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylaminoor —OM, where M is an ammonium, tetra-alkyl ammonium, sodium, potassium,magnesium or zinc cation; W is hydrogen, alkyl, alkenyl, alkynyl, aryl,heteroaryl, halo, hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino,dialkylamino, acylamino, carboxamido, or sulfonamide; R^(a)-R^(c) areindependently selected from a group consisting of hydrogen, alkyl, aryl,acyl or alkoxyacyl; the integer n is zero, one or two; the integer m isone or two; and the two substituents on ring X are ortho-, meta- orpara-; and (b) an excipient comprising polyalkylene glycol, polyglycolicacid, polylactic acid, or a copolymer or combination thereof.
 2. Thepharmaceutical composition of claim 1, wherein the active agentcomprises a compound having the structure of any one of formulae 2-7:

wherein A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylaminoor —OM, where M is an ammonium, tetra-alkyl ammonium, sodium, potassium,magnesium or zinc cation; W is hydrogen, alkyl, alkenyl, alkynyl, aryl,heteroaryl, halo, hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino,dialkylamino, acylamino, carboxamido, or sulfonamide; R^(a)-R^(c) areindependently selected from a group costing of hydrogen, alkyl, aryl,acyl or alkoxyacyl; the integer n is zero, one or two; the integer m isone or two.
 3. The pharmaceutical composition of claim 1, wherein theactive agent comprises a compound having the structure of any one offormulae 8-19:

wherein A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylaminoor —OM, where M is an ammonium, tetra-alkyl ammonium, sodium, potassium,magnesium or zinc cation; W is hydrogen, alkyl, alkenyl, alkynyl, aryl,heteroaryl, halo, hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino,dialkylamino, acylamino, carboxamido, or sulfonamide; R^(a)-R^(c) areindependently selected from a group costing of hydrogen, alkyl, aryl,acyl or alkoxyacyl; the integer n is zero, one or two; the integer m isone or two.
 4. The pharmaceutical composition of claim 3, wherein W isalkyl or aryloxy.
 5. The pharmaceutical composition of claim 1, whereinthe active agent comprises a compound having the structure of

wherein A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylaminoor —OM, where M is an ammonium, tetra-alkyl ammonium, sodium, potassium,magnesium or zinc cation.
 6. The pharmaceutical composition of claim 5,wherein A is hydroxy or alkoxy.
 7. The pharmaceutical composition ofclaim 1, wherein the active agent comprises (5S,6R,E)-methyl5,6-dihydroxy-8-(3-((R,E)-3-hydroxyoct-1-enyl)phenyl)oct-7-enoate


8. The pharmaceutical composition of claim 1, wherein the excipientcomprises polyalkylene glycol.
 9. The pharmaceutical composition ofclaim 1, wherein the excipient is polyethylene glycol, polypropyleneglycol, propylene glycol monostearate, diethylene glycol monolaurate,polyethylene glycol 4000, polyethylene glycol-350-dimethyl ether,polyethylene glycol-550-dimethyl ether, or polyethyleneglycol-750-dimethyl ether.
 10. The pharmaceutical composition of claim1, wherein the excipient is polyethylene glycol.
 11. The pharmaceuticalcomposition of claim 1, wherein the excipient comprises polyglycolicacid.
 12. The pharmaceutical composition of claim 1, wherein theexcipient comprises polylactic acid.
 13. The pharmaceutical compositionof claim 1, wherein the excipient comprises polyglycolic acid andpolylactic acid.
 14. The pharmaceutical composition of claim 1, whereinthe excipient comprises a copolymer of polyglycolic acid and polylacticacid.
 15. The pharmaceutical composition of claim 1, in the form of asolution, suspension, tablet, dispersible tablet, pill, capsule, powder,liposome, oil-water emulsion, sustained release formulation or elixir.16. The pharmaceutical composition of claim 1, in the form of a chewablelozenge, enteric-coated tablet, sugar-coated tablet, film-coated tablet,hard capsule soft gelatin capsule, non-effervescent granule,effervescent granule, non-effervescent powder or effervescent powder.17. The pharmaceutical composition of claim 1, in the form of a liquidsolution, liquid suspension, solid form suitable for solution orsuspension in liquid prior to injection, or emulsion.
 18. Thepharmaceutical composition of claim 1, in the form of a cream, gel,ointment, emulsion, solution, elixir, lotion, suspension, tincture,paste, foam, aerosol, irrigation, spray, suppository, bandage or dermalpatch.
 19. The pharmaceutical composition of claim 1, in the form of alyophilized powder that can be reconstituted for administration as asolution, emulsion, injection, or for parenteral administration.
 20. Thepharmaceutical composition of claim 1, in the form of a solution,suspension, emulsion, cream, gel, ointment, solution, elixir, lotion,suspension, tincture, paste, foam, aerosol, irrigation, spray,suppository, bandage, or dermal patch suitable for topicaladministration or for transdermal delivery.
 21. The pharmaceuticalcomposition of claim 1, in the form of an aerosol for administration tothe respiratory tract in the form of an aerosol or solution for anebulizer, or as a microfine powder for insufflation, alone or incombination with an inert carrier.
 22. The pharmaceutical composition ofclaim 1, wherein n is one or two, and the two substituents on ring X aremeta- or para-.
 23. The pharmaceutical composition of claim 1, whereinm-n is zero or one, and the two substituents on ring X are meta- orpara-.
 24. The pharmaceutical composition of claim 1, wherein the twosubstituents on ring X are meta-.